CELC ▲ +0.4% - Celcuity Inc.
$CELC - Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
23-OCT-2026 09:15 AM ET
Share this post
More filings for $CELC
CELC ▼ -3.4% - Celcuity Inc.Nov 9, 2026CELC ▼ -7.6% - Celcuity Inc.Nov 5, 2026CELC ▼ -7.6% - Celcuity Inc.Nov 5, 2026CELC ▼ -0.0% - Celcuity Inc.Nov 3, 2026CELC ▼ -0.1% - Celcuity Inc.Oct 29, 2026CELC ▼ -3.6% - Celcuity Inc.Oct 24, 2026
View full $CELC filing history →💬 Comments
Loading comments…
Leave a comment